GeneDx Holdings Corp.
NASDAQ Global SelectTotal Valuation
GeneDx Holdings Corp. carries a market capitalization of 5,788.00, placing it among publicly traded companies globally. Its enterprise value stands at 34.97M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 5,788.00 |
| Enterprise Value | 34.97M |
Share Statistics
GeneDx Holdings Corp. currently has 29.80M shares outstanding.
| Shares Outstanding | 29.80M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Enterprise Valuation
| EV / Sales | 0.08 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
GeneDx Holdings Corp. maintains a current ratio of 3.30, meaning it holds 3.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 68.55, indicating elevated leverage, while an interest coverage ratio of -16.84 demonstrates limited ability to service its debt obligations.
| Current Ratio | 3.30 |
| Quick Ratio | 2.90 |
| Debt / Equity | 68.55 |
| Debt / EBITDA | -5.23 |
| Interest Coverage | -16.84 |
Financial Efficiency
| Return on Equity (ROE) | -40.80 |
| Return on Assets (ROA) | -22.50 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 9.36 |
Taxes
| Income Tax | 62,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
GeneDx Holdings Corp.'s stock has declined approximately -99.80639% over the past 52 weeks. The 50-day moving average sits at 0.01, while the 200-day moving average is 0.03.
| Beta (5Y) | N/A |
| 52-Week Price Change | -99.80639% |
| 50-Day Moving Average | 0.01 |
| 200-Day Moving Average | 0.03 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -32.03M, while operating income came in at -58.91M.
| Revenue | 454.43M |
| Gross Profit | 315.24M |
| Operating Income | -58.91M |
| Pretax Income | -106.29M |
| Net Income | -106.36M |
| EBITDA | -32.03M |
| EBIT | -58.91M |
| Earnings Per Share (EPS) | N/A |
Balance Sheet
GeneDx Holdings Corp. holds 132.55M in cash and equivalents against 167.40M in total debt, resulting in a net debt position of 36.52M. Total book value stands at 244.22M, with working capital of 171.73M providing operational flexibility.
| Cash & Cash Equivalents | 132.55M |
| Total Debt | 167.40M |
| Net Debt | 36.52M |
| Equity (Book Value) | 244.22M |
| Book Value Per Share | 8.19 |
| Working Capital | 171.73M |
Cash Flow
GeneDx Holdings Corp. produced -48.71M in operating cash flow over the past twelve months.
| Operating Cash Flow | -48.71M |
| Capital Expenditures | -27.09M |
| Free Cash Flow | -75.80M |
| FCF Per Share | N/A |
Margins
GeneDx Holdings Corp. operates with a gross margin of 69.37, reflecting its pricing power and cost economics. The operating margin of -12.96 and net profit margin of -23.40 provide insight into operational efficiency.
| Gross Margin | 69.37 |
| Operating Margin | -12.96 |
| Pretax Margin | -23.39 |
| Profit Margin | -23.40 |
| EBITDA Margin | -7.05 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -61,701.50 |
| FCF Yield | N/A |
Scores
GeneDx Holdings Corp. posts an Altman Z-Score of -4.64, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -4.64 |